NASDAQ:PTGX - Protagonist Therapeutics Stock Price, Forecast & News

Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX."

Protagonist Therapeutics Inc (NASDAQ:PTGX) issued its earnings results on Wednesday, November, 6th. The company reported ($0.61) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.10. The business earned $4.14 million during the quarter, compared to the consensus estimate of $5.75 million. View Protagonist Therapeutics' Earnings History.

Protagonist Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Protagonist Therapeutics.

5 brokerages have issued twelve-month price targets for Protagonist Therapeutics' stock. Their forecasts range from $17.00 to $29.00. On average, they anticipate Protagonist Therapeutics' stock price to reach $21.50 in the next twelve months. This suggests a possible upside of 143.8% from the stock's current price. View Analyst Price Targets for Protagonist Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Protagonist Therapeutics.

News coverage about PTGX stock has trended negative recently, InfoTrie reports. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Protagonist Therapeutics earned a coverage optimism score of -2.7 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Protagonist Therapeutics.

Protagonist Therapeutics saw a drop in short interest during the month of January. As of January 31st, there was short interest totalling 1,240,000 shares, a drop of 20.5% from the January 15th total of 1,560,000 shares. Based on an average daily volume of 660,800 shares, the days-to-cover ratio is presently 1.9 days. Approximately 6.5% of the company's shares are sold short. View Protagonist Therapeutics' Current Options Chain.

Some companies that are related to Protagonist Therapeutics include Endonovo Therapeutics (ENDV), Kiniksa Pharmaceuticals (KNSA), Achillion Pharmaceuticals (ACHN), Radius Health (RDUS), ImmunoGen (IMGN), Stoke Therapeutics (STOK), Amphastar Pharmaceuticals (AMPH), Applied Therapeutics (APLT), Homology Medicines (FIXX), Phathom Pharmaceuticals (PHAT), Dova Pharmaceuticals (DOVA), Rhythm Pharmaceuticals (RYTM), ANI Pharmaceuticals (ANIP), Collegium Pharmaceutical (COLL) and CannTrust (CNTTF).

Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include Strongbridge Biopharma (SBBP), Agile Therapeutics (AGRX), Viking Therapeutics (VKTX), vTv Therapeutics (VTVT), Energy Transfer LP Unit (ET), Genocea Biosciences (GNCA), ImmunoGen (IMGN), Nabriva Therapeutics (NBRV), Novavax (NVAX) and SCYNEXIS (SCYX).

(PTGX) raised $70 million in an initial public offering on Thursday, August 11th 2016. The company issued 5,800,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets acted as the underwriters for the IPO.

Protagonist Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), Renaissance Technologies LLC (2.27%), State Street Corp (1.24%), Jacobs Levy Equity Management Inc. (0.34%), Bank of New York Mellon Corp (0.31%) and Ikarian Capital LLC (0.29%). Company insiders that own Protagonist Therapeutics stock include Bryan Giraudo, David Y Liu, Dinesh V Ph D Patel, Donald A Kalkofen, Richard S Shames, Suneel Gupta and X LP Canaan. View Institutional Ownership Trends for Protagonist Therapeutics.

PTGX stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Oxford Asset Management LLP, Russell Investments Group Ltd., Bank of America Corp DE and Eqis Capital Management Inc.. Company insiders that have sold Protagonist Therapeutics company stock in the last year include David Y Liu, Dinesh V Ph D Patel and Richard S Shames. View Insider Buying and Selling for Protagonist Therapeutics.

PTGX stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Ikarian Capital LLC, Jacobs Levy Equity Management Inc., Renaissance Technologies LLC, Prudential Financial Inc., Spark Investment Management LLC, State Street Corp and Strs Ohio. Company insiders that have bought Protagonist Therapeutics stock in the last two years include Bryan Giraudo, Donald A Kalkofen and Suneel Gupta. View Insider Buying and Selling for Protagonist Therapeutics.

Shares of PTGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PTGX stock can currently be purchased for approximately $8.82.

Protagonist Therapeutics has a market capitalization of $239.99 million and generates $30.92 million in revenue each year. The company earns $-38,920,000.00 in net income (profit) each year or ($1.74) on an earnings per share basis. Protagonist Therapeutics employs 64 workers across the globe.View Additional Information About Protagonist Therapeutics.

The official website for Protagonist Therapeutics is http://www.protagonist-inc.com/.

Protagonist Therapeutics' mailing address is 7707 GATEWAY BLVD. SUITE 140, NEWARK CA, 94560. The company can be reached via phone at 510-474-0170 or via email at [email protected]